Summary
The effects on ventilation of the non-selective beta-blocker propranolol, and the relatively cardioselective beta-blocker, metoprolol, were compared in a randomized single-blind crossover study in 16 patients with asthma, bronchitis and emphysema (American Thoracic Society critieria). Group I had “fixed” airways disease with <20% improvement in FEV1 following inhaled salbutamol 5 mg by nebuliser. Group II had “reversible” obstruction, >20% improvement. Bronchodilator therapy was withheld for 24h with the exception of aerosols which were permitted until 12h before study. After control observations on each of 2 study days, each patient received cumulative dosese of propranolol (maximum 170 mg) and metoprolol (maximum 187.5 mg). Ventilatory function (FEV1, FVC, FEV1%) was assessed at 0, 2, 4, 6 and 8h. In Group I, 2 patients were unable to complete the study. One patient became dizzy with propranolol 70 mg but tolerated metoprolol 187.5 mg. One patient developed wheeze with propranolol 15 mg but tolerated metoprolol 187.5 mg. Metoprolol was tolerated in all 8 patients with “fixed” disease, although FEV1 was reduced by more than 30% in 1 patient. Three patients in Group II did not complete the study because of wheezing following propranolol 10 mg, metoprolol 37.5 mg; propranolol 17.5 mg, metoprolol 37.5 mg; propranolol 45 mg, tolerated metoprolol 187.5 mg respectively. Wheezing responded in all cases to inhaled isoprenaline. The response to either propranolol or metoprolol was unpredictable in patients with “reversible” disease. When wheezing occurred in this group, it developed following small, potentially subtherapeutic doses of each drug. Although metoprolol was better tolerated, the practical benefit of cardioselectivity in those patients with reversible airways disease was negligible.
Similar content being viewed by others
References
American Thoracic Society (1962) Statement by the committee on diagnostic standards for non-tuberculous respiratory diseases: definitions and classifications of chronic bronchitis, asthma, and pulmonary emphysema. Am Rev Respir Dis 85: 762–768
Abraham TA, Hasan FM, Fenster PE, Mercer FI (1981) Effect of intravenous metoprolol on reversible obstructive airways disease. Clin Pharmacol Ther 29: 582–587
Benson MK, Berrill WT, Cruickshank JM, Sterlin GM (1978) A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 5: 415–419
Carlsson E, Ablad B, Brandstrom A, Carlsson B (1972) Differentiated blockade of the chronotropic effects of various adrenergic stimuli in the cat heart. Life Sci (Part I) 2: 953–958
Carruthers SG (1979) Cardioselectivity of beta-blockers: theoretical aspects. In: Roberts RH (eds) Theories and use of beta-blockers in hypertension and angina. Symposia Specialists Miami, FL, pp 125–139
Chester EH, Schwartz HJ, Fleming GM (1981) Adverse effects of propranolol on airways function in non-asthmatic chronic obstructive lung disease. Chest 79: 540–544
Gribbon HR, Baldwin CJ, Tattersfield AE (1979) Quantitative assessment of bronchial B-adrenoceptor blockade in man. Br J Clin Pharmacol 7: 551–556
Johnsson G, Svedmyr N, Thiringer G (1975) Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics. Eur J Clin Pharmacol 8: 175–180
Kumana CR, Marlin GE, Kaye CM, Smith DM (1974) New approach to assessment of cardioselectivity of beta-blocking drugs. Br Med J 4: 444–447
Lands AM, Luduena FP, Buzzo HJ (1967) Differentiation of receptors responsive to isoproterenol. Life Sci 6: 2241–2249
Lertora JJL, Mark AL, Johannsen UJ, Wilson WR, Abboud FM (1975) Selective beta-receptor blockade with oral practalol in man a dose related phenomenon. J Clin Invest 56: 719–724
McDevitt DG (1977) The assessment of beta-adrenoreceptor blocking drugs in man. Br J Clin Pharmacol 4: 413–425
McDevitt DG (1978) Beta-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol 5: 97–99
McDevitt DG, Johnston GD (1980) Principles of evaluation of human pharmacodynamics with particular reference to the cardiovascular and respiratory systems. In: Turner P, Shand DG (eds) Advances in clinical pharmacology. Churchill, London, pp 1–17
McGavin CR, Williams IP (1978) The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 72: 327–332
McNeill RS (1964) Effect of a beta-adrenergic blocking agent, propranolol on asthmatics. Lancet 2: 1101–1102
Oh VMS, Kaye CM, Warrington SJ, Taylor EA, Wadsworth J (1978) Studies of cardioselectivity and partial agonist activity in beta-adrenoreceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. Br J Clin Pharmacol 5: 107–120
Palmer KNV (1977) Respiratory side-effects of beta-blockers. Br Med J 1: 841
Perks WH, Chatterjee SS, Croxson RS, Cruickshank JM (1978) Comparison of atenolol and oxprenolol in patients with angina or hypertension and coexistent airways obstruction. Br J Clin Pharmacol 5: 101–106
Raine JM, Palazzo MG, Kerr JH, Sleight P (1981) Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J 1: 548–549
Schwartz S, Davies S, Juens JA (1980) Life threatening cold and exercise-induced asthma potentiated by administration of propranolol. Chest 78: 100–104
Sinclair DJM (1979) Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis. Br Med J 1: 168
Singh BN, Phil D, Robert ML, Whitlock MB, Russell H, Comber MB, Williams FH, Harris EA (1976) Effects of cardioselective beta-adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther 19: 493–501
Skinner C (1981) Beta-blockers in asthma. Br Med J 1: 901–902
Skinner C, Gaddie J, Palmer KNV, Kerridge DF (1976) Comparison of effect of metoprolol and propranolol on asthmatic airway obstruction. Br Med J 1: 504
Thiringer B, Svedmyr N (1976) Interaction of orally administered metoprolol, practolol and propanolol with isoprenaline in asthmatics. Eur J Clin Pharmacol 10: 163–170
Twum-Barima Y, Ahmad D, Hamilton JT, Carruthers SG (1982) Lack of effect of beta-adrenergic drugs on the hyperventilatory response to carbon dioxide in normal subjects. Clin Pharmacol Ther 32: 289–294
Wunderlich J, Macha HW, Wudicke H, Huckauf H (1980) Beta-adrenoreceptor blockers and terbutaline in patients with chronic obstructive lung disease. Chest 78: 714–720
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clague, H.W., Ahmad, D. & Carruthers, S.G. Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade. Eur J Clin Pharmacol 27, 517–523 (1984). https://doi.org/10.1007/BF00556885
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00556885